@FierceBiotech
www.fiercebiotech.com MetaVia sees GLP-1 shed liver fat and body weight in phase 1, takes aim at specific liver disease MetaVia has 
www.fiercebiotech.com Rezera revs up for $181M IPO to fund phase 3 trial of NLRP3 inhibitor Rezera—the new name for NodThera—is aiming for a $181 million IPO to take | Rezera—the new name for NodThera—is aiming for a $181 million IPO to take its NLRP3 inhibitor into phase 3 trials for a... 
www.fiercebiotech.com Evommune signs $1B deal with China’s Hinova to enter same molecular glue niche as Novartis Evommune has agreed to 
www.fiercebiotech.com Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic Sanofi has decided to 
www.fiercebiotech.com Ultragenyx shrinks workforce and axes assets to halve R&D spend Ultragenyx is laying off 20% of its workforce and a | Ultragenyx is laying off 20% of its workforce and axing drug development programs to cut its annual R&D budget to half of the amount it spent in... 